Skip to main content

Multiple System Atrophy

13
Pipeline Programs
14
Companies
21
Clinical Trials
6 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
8
0
2
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
150%
Gene Therapy
150%
+ 17 programs with unclassified modality

Competitive Landscape

14 companies ranked by most advanced pipeline stage

Lundbeck
LundbeckDenmark - Copenhagen
3 programs
2
1
AmlenetugPhase 31 trial
Lu AF82422Phase 21 trial
rasagiline mesylatePhase 21 trial
Active Trials
NCT05104476Active Not Recruiting64Est. Mar 2028
NCT00977665Completed174Est. Oct 2011
NCT06706622Active Not Recruiting401Est. Oct 2029
Rare Disease Therapeutics
1 program
1
RifampicinPhase 31 trial
Active Trials
NCT01287221Terminated100Est. Jan 2013
Alterity Therapeutics
Alterity TherapeuticsAustralia - Melbourne
3 programs
2
ATH434Phase 22 trials
ATH434 dose level 1Phase 21 trial
ATH434N/A1 trial
Active Trials
NCT07531433Available
NCT07729852Not Yet Recruiting5Est. Jul 2029
NCT05864365Completed10Est. Feb 2025
+1 more trials
Tiziana Life Sciences
Tiziana Life SciencesLONDON, ENGLAND, United Kingdom
1 program
1
Foralumab NasalPhase 21 trial
Active Trials
NCT06868628Recruiting5Est. Apr 2027
Zambon
ZambonItaly - Bresso
1 program
1
Safinamide MethanesulfonatePhase 21 trial
Active Trials
NCT03753763Completed49Est. Jan 2021
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
TAK-341Phase 2
Yoda Therapeutics
Yoda TherapeuticsTaiwan - Taipei
1 program
1
YA-101Phase 21 trial
Active Trials
NCT06848231Recruiting75Est. Dec 2026
Corestemchemon
CorestemchemonKorea - Seongnam
2 programs
1
CS10BR05Phase 11 trial
Long-term Follow-up of Phase 1 Clinical Trial of CS10BR05(CS10BR05-MSA101)N/A1 trial
Active Trials
NCT04495582Completed8Est. Sep 2024
NCT03265444Completed9Est. Dec 2019
Biocorp
BiocorpFrance - Issoire
1 program
1
AAV2-GDNF gene therapyPhase 1Gene Therapy1 trial
Active Trials
NCT04680065Active Not Recruiting9Est. Aug 2028
AFFiRiS
AFFiRiSAustria - Vienna
1 program
1
AFFITOPE® PD01A + AdjuvantPhase 11 trial
Active Trials
NCT02270489Completed30Est. Apr 2017
Ionis Pharmaceuticals
1 program
ION464PHASE_11 trial
Active Trials
NCT04165486Recruiting40Est. Sep 2027
Parexel
ParexelMA - Boston
1 program
KM-819PHASE_21 trial
Active Trials
NCT05695378Terminated68Est. Aug 2024
Teva
TevaIsrael - Petach Tikva
1 program
TEV-56286PHASE_23 trials
Active Trials
NCT07674940Recruiting60Est. Jan 2027
NCT07197866Recruiting200Est. May 2029
NCT06568237Recruiting350Est. Sep 2027
Biohaven
BiohavenNEW HAVEN, CT
1 program
VerdiperstatPHASE_3Small Molecule1 trial
Active Trials
NCT03952806Completed421Est. Jun 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
LundbeckAmlenetug
BiohavenVerdiperstat
Rare Disease TherapeuticsRifampicin
Alterity TherapeuticsATH434
TevaTEV-56286
Tiziana Life SciencesForalumab Nasal
Yoda TherapeuticsYA-101
TevaTEV-56286
Alterity TherapeuticsATH434
ParexelKM-819
Alterity TherapeuticsATH434 dose level 1
LundbeckLu AF82422
ZambonSafinamide Methanesulfonate
Lundbeckrasagiline mesylate
TevaTEV-56286

Showing 15 of 20 trials with date data

Clinical Trials (21)

Total enrollment: 2,155 patients across 21 trials

NCT06706622LundbeckAmlenetug

A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)

Start: Dec 2024Est. completion: Oct 2029401 patients
Phase 3Active Not Recruiting
NCT03952806BiohavenVerdiperstat

Study of BHV-3241 in Participants With Multiple System Atrophy

Start: Jul 2019Est. completion: Jun 2022421 patients
Phase 3Completed
NCT01287221Rare Disease TherapeuticsRifampicin

Study of Rifampicin in Multiple System Atrophy

Start: Mar 2011Est. completion: Jan 2013100 patients
Phase 3Terminated
NCT07729852Alterity TherapeuticsATH434

Open-Label Access to ATH434 for Patients Who Completed Study ATH434-201 in France

Start: Jul 2026Est. completion: Jul 20295 patients
Phase 2Not Yet Recruiting
NCT07197866TevaTEV-56286

An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy

Start: Sep 2025Est. completion: May 2029200 patients
Phase 2Recruiting
NCT06868628Tiziana Life SciencesForalumab Nasal

A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)

Start: May 2025Est. completion: Apr 20275 patients
Phase 2Recruiting
NCT06848231Yoda TherapeuticsYA-101

A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy

Start: Mar 2025Est. completion: Dec 202675 patients
Phase 2Recruiting
NCT06568237TevaTEV-56286

A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy

Start: Oct 2024Est. completion: Sep 2027350 patients
Phase 2Recruiting
NCT05864365Alterity TherapeuticsATH434

A Biomarker Study of ATH434 in Participants With MSA

Start: May 2023Est. completion: Feb 202510 patients
Phase 2Completed
NCT05695378ParexelKM-819

Trial to Evaluate the Efficacy and Safety of KM-819 Treatment to Slow the Progression of Multiple System Atrophy (MSA)

Start: Feb 2023Est. completion: Aug 202468 patients
Phase 2Terminated
NCT05109091Alterity TherapeuticsATH434 dose level 1

Study of ATH434 in Participants with Multiple System Atrophy

Start: Jul 2022Est. completion: Nov 202477 patients
Phase 2Completed
NCT05104476LundbeckLu AF82422

A Study of Lu AF82422 in Participants With Multiple System Atrophy

Start: Nov 2021Est. completion: Mar 202864 patients
Phase 2Active Not Recruiting
NCT03753763ZambonSafinamide Methanesulfonate

Safinamide for Multiple System Atrophy (MSA)

Start: Oct 2019Est. completion: Jan 202149 patients
Phase 2Completed
NCT00977665Lundbeckrasagiline mesylate

Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)

Start: Dec 2009Est. completion: Oct 2011174 patients
Phase 2Completed
NCT07674940TevaTEV-56286

A Trial to Assess TEV-56286 at Different Doses in Healthy Participants

Start: Jun 2026Est. completion: Jan 202760 patients
Phase 1Recruiting
NCT04680065BiocorpAAV2-GDNF gene therapy

GDNF Gene Therapy for Multiple System Atrophy

Start: Oct 2023Est. completion: Aug 20289 patients
Phase 1Active Not Recruiting
NCT04165486Ionis PharmaceuticalsION464

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)

Start: Jul 2022Est. completion: Sep 202740 patients
Phase 1Recruiting
NCT03265444CorestemchemonCS10BR05

Safety and Tolerability of CS10BR05 Inj. in Subjects with Multiple System Atrophy

Start: Apr 2018Est. completion: Dec 20199 patients
Phase 1Completed
NCT02270489AFFiRiSAFFITOPE® PD01A + Adjuvant

Study Assessing Safety and Therapeutic Activity of AFFITOPE® PD01A and PD03A in Patients With Early MSA

Start: Dec 2014Est. completion: Apr 201730 patients
Phase 1Completed
NCT07531433Alterity TherapeuticsATH434

Post-Trial Access to ATH434 for Patients With Multiple System Atrophy

N/AAvailable
NCT04495582CorestemchemonLong-term Follow-up of Phase 1 Clinical Trial of CS10BR05(CS10BR05-MSA101)

Long-term Follow-up of Phase 1 Clinical Trial of CS10BR05(CS10BR05-MSA101)

Start: Aug 2018Est. completion: Sep 20248 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
6 actively recruiting trials targeting 2,155 patients
14 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.